1-20 of 61
Arnon P. Kater, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial)

Sabina Kersting, MD PhD, Mark-David Levin, MD PhD, Carsten Utoft Niemann, MD PhD, Yvette Norden, PhD, Arnon P. Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1753.
https://doi.org/10.1182/blood-2019-124550
Published: 2019
Journal Articles

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Barbara F. Eichhorst, MD, Peter Hillmen, MD PhD, James D'Rozario, MBBS, FRACP, FRCPA, Sarit Assouline, MD, Carolyn Owen, MD, Tadeusz Robak, MD, Javier de la Serna, MD PhD, Ulrich Jaeger, MD, Guillaume Cartron, Marco Montillo, MD, Nicole Lamanna, MD, Su Young Kim, MD PhD, Jenny Wu, MS, Yanwen Jiang, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Arnon P Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 355.
https://doi.org/10.1182/blood-2019-123930
Published: 2019
Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Arnon P Kater, MD PhD, Jenny Qun Wu, MS, Julie Dubois, Christopher R Bolen, PhD, Zoe J Assaf, PhD, Peter Hillmen, MD PhD, Barbara F. Eichhorst, MD, Eric F Eldering, PhD, Thomas J. Kipps, MD PhD, Anton W Langerak, PhD, Clemens Mellink, PhD, Anne-Marie Van Der Kevie-Kersemaekers, PhD, Carolyn Owen, MD, Brenda J Chyla, PhD, Elizabeth A Punnoose, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Yanwen Jiang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 356.
https://doi.org/10.1182/blood-2019-123678
Published: 2019
Journal Articles

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

Jennifer R Brown, MD PhD, Barbara F. Eichhorst, MD, Paolo Ghia, MD PhD, Arnon P. Kater, MD PhD, Jianyong Li, MD, Sudha Khurana, Mostafa Elhamy, Min Hui Wang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 4318.
https://doi.org/10.1182/blood-2019-123057
Published: 2019
Journal Articles

CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction

Anne W. J. Martens, MSc, Susanne R. Janssen, MSc, Ingrid A.M. Derks, Sanne Tonino, MD PhD, Eric Eldering, Gerritje J. W. van der Windt, Arnon P. Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3043.
https://doi.org/10.1182/blood-2019-123350
Published: 2019
Journal Articles

Combined Ibrutinib and Venetoclax Changes Myeloid Phenotype and Improves Immune Function in CLL Patients

Rebecka Svanberg, MD, Sisse Rye Ostrowski, MD PhD DMSc, Ass Prof, Jakob Thaning Bay, MD PhD, Lars Peter Ryder, MSc, PhD, Hanne Vibeke Vibeke Marquart, Arnon P Kater, MD PhD, Carsten Utoft Niemann, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4289.
https://doi.org/10.1182/blood-2019-123410
Published: 2019
Journal Articles

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Carsten Utoft Niemann, MD PhD, Julie Dubois, Sabina Kersting, MD PhD, Lisbeth Enggaard, MD, Gerrit J Veldhuis, Rogier Mous, MD PhD, Clemens Mellink, PhD, Johan A Dobber, Christian Bjørn Poulsen, MD, Henrik Frederiksen, MD Prof, Ann Janssens, Ida Schjødt, MD PhD, Ellen C Dompeling, Juha Ranti, Mattias Mattsson, MD, Mar Bellido, Hoa T Tran, Kazem Nasserinejad, Mark-David Levin, MD PhD, Arnon P. Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4292.
https://doi.org/10.1182/blood-2019-124377
Published: 2019
Journal Articles

Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Simon Rule, MD, Pier Luigi Zinzani, MD, Andre Goy, MD, Olivier Casasnovas, MD, Stephen D. Smith, MD, Gandhi Damaj, MD PhD, Jeanette K. Doorduijn, MD PhD, Thierry Lamy, Franck Morschhauser, MD, Carlos Panizo, MD PhD, Bijal D. Shah, MD, Andrew Davies, Richard Eek, MBCHB, Jehan Dupuis, MD, Eric Jacobsen, MD, Arnon P. Kater, MD PhD, Steven LE Gouill, MD PhD, Lucie Oberic, MD, Tadeusz Robak, MD PhD, Richa Dua, PharmD, Melanie M. Frigault, PhD, Raquel Izumi, PhD, Dorothy Nguyen, MD PhD, Priti Patel, MD, Ming Yin, PhD, Wojciech Jurczak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2876.
https://doi.org/10.1182/blood-2018-99-110327
Published: 2018
Journal Articles

Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8 + T Cells and Impede CAR T Cell Efficacy

Jaco A. C. Van Bruggen, MSc, Anne W. J. Martens, MSc, Joseph A Fraietta, PhD, Tom Hofland, MSc, Sanne Tonino, MD PhD, Eric Eldering, PhD, Mark-David Levin, MDPhD, Peter J. Siska, MD, Sanne Endstra, Jeffrey C Rathmell, PhD, Carl H June, MD, David L. Porter, MD, J. Joseph Melenhorst, PhD, Gerritje J. W. van der Windt, PhD, Arnon P. Kater, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 235.
https://doi.org/10.1182/blood-2018-99-115911
Published: 2018
Journal Articles

A New Therapeutic Hypothesis: Nonsense-Mediated Decay Is an Exploitable Target in Multiple Myeloma

Alexander Leeksma, MD, Ingrid A.M. Derks, Brett Garrick, Torsten Trowe, Aldo Jongejan, PhD, Perry Moerland, PhD, Arnon P. Kater, MD, Eric Eldering, PhD, Ellen Filvaroff, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1937.
https://doi.org/10.1182/blood-2018-99-114801
Published: 2018
Journal Articles

First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

Arnon P. Kater, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Barbara Eichhorst, Anton W Langerak, Thomas J. Kipps, MD PhD, Carolyn Owen, Michelle Boyer, Kathryn Humphrey, Elizabeth A Punnoose, Jue Wang, Brenda Chyla, Maria E. Verdugo, Jenny Wu, Yanwen Jiang, Mehrdad Mobasher, MD MPH, John F. Seymour, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 185.
https://doi.org/10.1182/blood-2018-99-117050
Published: 2018
Journal Articles

First Evidence of Dysfunctional Antigen-Specific T Cell Responses in Experimental CLL As a Model for Studies of Autologous T Cell-Based Therapies

Anne W. J. Martens, MSc, Felix M Wensveen, PhD, Ramon Arens, PhD, Eric Eldering, PhD, Gerritje J. W. van der Windt, PhD, Arnon P. Kater, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3694.
https://doi.org/10.1182/blood-2018-99-114679
Published: 2018
Journal Articles

First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment

Iris de Weerdt, MD, Tom Hofland, MSc, Johan Dobber, Julie Dubois, Eric Eldering, PhD, Mehrdad Mobasher, MD MPH, Fransien Croon-de Boer, Mels Hoogendoorn, MD PhD, Gerjo A. Velders, PhD MD, Marjolein van der Klift, Mark-David Levin, MD PhD, Sabina Kersting, MDPhD, Sanne Tonino, MD PhD, Arnon P. Kater, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1860.
https://doi.org/10.1182/blood-2018-99-116283
Published: 2018
Journal Articles

MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, MBBS, PhD, Thomas J. Kipps, MD PhD, Barbara Eichhorst, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, James D'Rozario, Sarit Assouline, Carolyn Owen, Tadeusz Robak, MD PhD, Javier de la Serna, Ulrich Jaeger, MD, Guillaume Cartron, Marco Montillo, MD, Nicole Lamanna, MD, Maria E. Verdugo, Elizabeth A Punnoose, Yanwen Jiang, Jue Wang, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, MD MPH, Arnon P. Kater, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 184.
https://doi.org/10.1182/blood-2018-184
Published: 2018
Journal Articles

Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study

John F Seymour, MBBS, PhD, Thomas J. Kipps, MD, Barbara F. Eichhorst, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, James M. D'Rozario, MBBS FRACP FRCPA, Sarit Assouline, MD, Carolyn Jane Owen, MD FRCPC, John Gerecitano, MD PhD, Tadeusz Robak, MD PhD, Javier De la Serna, MD, Ulrich Jaeger, MD, Guillaume Cartron, MD PhD, Marco Montillo, MD, Rod Humerickhouse, MD PhD, Elizabeth Punnoose, PhD, Yan Li, PhD, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Mehrdad Mobasher, MD, MPH, Arnon P. Kater, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): LBA-2.
https://doi.org/10.1182/blood.V130.Suppl_1.LBA-2.LBA-2
Published: 2017
Journal Articles

Cross-Talk between Cytokine and NF-ĸB Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax

Rachel Thijssen, Marco Haselager, Elaine Willmore, Simon Mackay, Arnon P. Kater, MD, Eric Eldering
Journal: Blood
Blood (2017) 130 (Supplement 1): 4306.
https://doi.org/10.1182/blood.V130.Suppl_1.4306.4306
Published: 2017
Journal Articles

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Fie Juhl Vojdeman, MD, Lone Bredo Pedersen, Doreen Te Raa, MD PhD, Vesa Juvonen, PhD, Yvette Norden, Geir Erland Tjønnfjord, MD DMsc, Eva Kimby, Maija Itälä-Remes, MD PhD, Anton W Langerak, Ludo M. Evers, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD PhD, Christian H. Geisler, MD PhD, Arnon P. Kater, MD, Carsten Utoft Niemann, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4312.
https://doi.org/10.1182/blood.V130.Suppl_1.4312.4312
Published: 2017
Journal Articles

Genomic Complexity in Chronic Lymphocytic Leukemia Defined By Array-Based Analysis: Definitions, Associations with Other Biomarkers and Clinical Impact

Alexander Leeksma, MD, Panagiotis Baliakas, MD PhD, Clemens Mellink, PhD, Theodoros Moysiadis, PhD BSc, MSc, Anna Puiggros, PhD, Karla Plevova, PhD, Eva van den Berg, PhD, Eric Eldering, Aron Skaftason, Larry Mansouri, Rebeqa Gunnarsson, PhD, Paolo Ghia, MD PhD, Blanca Espinet, PhD, Sarka Pospisilova, MD PhD, Florence Nguyen-Khac, MD PhD, David Oscier, MD PhD, Kostas Stamatopoulos, Claudia Haferlach, MD, Richard Rosenquist, MD PhD, Jonathan C Strefford, PhD, Marian Stevens-Kroef, PhD, Arnon P. Kater, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4280.
https://doi.org/10.1182/blood.V130.Suppl_1.4280.4280
Published: 2017
Journal Articles

Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial

Arnon P. Kater, MD, Marinus H.J. H.J. Van Oers, MD PhD, Yvette Norden, Roberto D. Liu, Martin R. Schipperus, Martine Chamuleau, MD PhD, Marcel Nijland, MD, Jeanette K. Doorduijn, MD PhD, Michel van Gelder, MDPhD, Mels Hoogendoorn, MDPhD, Fransien Croon-de Boer, Shulamit Wittebol, Martijn Kerst, MDPhD, Willem Marijt, Ward Posthuma, MD PhD, Reinier Raymakers, MDPhD, Ron Schaafsma, MDPhD, Johan Dobber, Sabina Kersting, MDPhD, Mark-David Levin
Journal: Blood
Blood (2017) 130 (Supplement 1): 4328.
https://doi.org/10.1182/blood.V130.Suppl_1.4328.4328
Published: 2017
Journal Articles

Combinatorial Treatment of Chronic Lymphocytic Leukemia with Ibrutinib and Venetoclax Is Superior to Treatment with Single Agents in the TCL1 Mouse Model

Erik Slinger, PhD, Sriram Balasubramanian, PhD, Joel D. Leverson, PhD, Eric Eldering, Arnon P. Kater, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3018.
https://doi.org/10.1182/blood.V130.Suppl_1.3018.3018
Published: 2017